Medipal Holdings (7459 JP): Better-Than-Expected FY23 Result; Accelerated Growth Expected in FY24
In FY23, Medipal Holdings’ revenue was 1% ahead of forecast, while net profit exceeded the guidance by 16%. The company guided for 3% YoY revenue...
406 Views
Jcr Pharmaceuticals (4552 JP): Mainstay Drug Revenue Declining; High R&D Cost Worsens Profitability
Revenue from JCR’s flagship drug Growject declined 7% to ¥9.3B during 9MFY23, due to the negative impact of insurance price. As R&D cost is...
378 Views
Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection
Green Cross is set to enter U.S. market through its immune globulin injection. However, FDA approval of the same got delayed as the agency couldn't...
373 Views
SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan
With promising clinical trial data and priority review status, SanBio’s lead drug candidate SB623 is expected to be approved in Japan this year....
624 Views
🇯🇵 JAPAN • Revisions 03/25 > Misumi & J. Front Retailing
Thursday saw only four micro-cap results, so we will again focus on just the forecasts and revisions, of which there were sixteen, with ten...
361 Views